<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291367</url>
  </required_header>
  <id_info>
    <org_study_id>BA085908801</org_study_id>
    <nct_id>NCT02291367</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition</brief_title>
  <official_title>Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study were to compare the relative bioavailability of Duloxetine HCl delayed release&#xD;
      capsule 60 mg with that of 'CYMBALTA®' delayed release capsule 60 mg (Duloxetine HCl delayed&#xD;
      release capsule 60 mg) in healthy, adult, human subjects under fasting conditions and to&#xD;
      monitor safety of subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized, two period, two treatment, two sequence, crossover, balanced, single&#xD;
      dose comparative oral bioavailability study in healthy, adult, human subjects under fasting&#xD;
      conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>1.0, 2.0,3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 9.0, 10.0, 11.0, 12.0, 24.0, 36.0, 48.0,60.0 and 72.0 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Duloxetine Delayed-Release Capsules, 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cymbalta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cymbalta® 60 mg capsule of Eli Lilly and Company</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine Delayed-Release Capsules 60 mg</description>
    <arm_group_label>Duloxetine Delayed-Release Capsules, 60 mg</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cymbalta®</intervention_name>
    <description>60 mg capsule of Eli Lilly and Company</description>
    <arm_group_label>Cymbalta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be healthy human between 18 and 45 years&#xD;
&#xD;
          2. Screened within 21 days prior to administration of first dose of study drug&#xD;
&#xD;
          3. Having a BMI between 18.5 and 24.9 weight in kg/ height2 in meter&#xD;
&#xD;
          4. Be able to communicate effectively with study personnel&#xD;
&#xD;
          5. Be able to give Written informed consent to participate in the study If subject is a&#xD;
             female volunteer and&#xD;
&#xD;
          6. is of child bearing potential practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator(s), such as condoms, foams,&#xD;
             jellies, diaphragm, intrauterine device (IUD), or abstinence.&#xD;
&#xD;
          7. is postmenopausal for at least 1 year.&#xD;
&#xD;
          8. is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy has been performed on the subject).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergic responses to Duloxetine or other related drugs.&#xD;
&#xD;
          2. Have significant diseases or clinically significant abnormal findings during&#xD;
             screening, medical history, physical examination, laboratory evaluations, ECG &amp; X-ray&#xD;
             recordings.&#xD;
&#xD;
          3. Any disease or condition which might compromise the haemopoeitic, gastrointestinal,&#xD;
             renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes,&#xD;
             psychosis or any other body system.&#xD;
&#xD;
          4. History or presence of bronchial asthma.&#xD;
&#xD;
          5. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of&#xD;
             study medication.&#xD;
&#xD;
          6. History of drug dependence, recent history of alcoholism or of moderate alcohol use.&#xD;
&#xD;
          7. Smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal&#xD;
             to 20 biddies per day or those who can not refrain from smoking during study period.&#xD;
&#xD;
          8. History of difficulty with donating blood or difficulty in accessibility of veins.&#xD;
             Donation of blood (I unit: 350 mL/450 mL) within 90 days prior to receiving the first&#xD;
             dose of study medication.&#xD;
&#xD;
          9. A positive hepatitis screen (includes subtypes A, B, C &amp; E)&#xD;
&#xD;
         10. A positive test result for HIV antibody and/or syphilis (RPR/VDRL).&#xD;
&#xD;
         11. The receipt of an investigational product, or participation in a drug research study&#xD;
             within a period of 90 days prior to the frst dose of study medication administration.&#xD;
&#xD;
         12. Female volunteers demonstrating a positive pregnancy screen&#xD;
&#xD;
         13. Female volunteers who are currently breast-feeding&#xD;
&#xD;
         14. Female volunteers not willing to use contraception during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayur Soni, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BA Research India Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

